Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C ROCKVILLE, MD--(Marketwire - March 9, 2009) - -- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable...

Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile ROCKVILLE, MD--(Marketwire - February 2, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced that it has begun delivery of 20,000 doses of its human monoclonal antibody drug...